Indaptus Therapeutics (NASDAQ:INDP) Price Target Cut to $5.00 by Analysts at Maxim Group

Indaptus Therapeutics (NASDAQ:INDP) had its target price lowered by investment analysts at Maxim Group from $8.00 to $5.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 329.18% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Indaptus Therapeutics in a research report on Wednesday, October 16th.

Indaptus Therapeutics Trading Up 1.3 %

NASDAQ:INDP traded up $0.02 during trading hours on Wednesday, hitting $1.17. 8,507 shares of the company were exchanged, compared to its average volume of 63,868. The stock has a market capitalization of $11.88 million, a price-to-earnings ratio of -0.68 and a beta of 1.45. Indaptus Therapeutics has a one year low of $1.03 and a one year high of $3.10. The company has a fifty day simple moving average of $1.33 and a 200 day simple moving average of $1.84.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Equities research analysts predict that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.17% of Indaptus Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.